Search results
Added:
1 week ago
HFA Congress 2026 — Dr Ambarish Pandey (University of Texas Southwestern Medical Center, Texas, US) joins us to discuss findings on diuretic resistance drawn from TRANSFORM-HF, a large-scale, pragmatic, randomised clinical effectiveness trial comparing torsemide versus furosemide in patients hospitalised with heart failure.TRANSFORM-HF enrolled 2,973 patients across 60 US sites, randomising 1:1…
View more
Added:
1 week ago
Heart Failure Association Congress 2026 — Dr Philippe Debonnaire (AZ Sint Jan, Brugge, BE) and Professor Victoria Delgado (University Hospital Germans Trias i Pujol, Badalona, SP) discuss the expanding role of advanced cardiac imaging in heart failure diagnosis and management, and what a more personalised, multimodality approach means for clinical practice.The conversation moves beyond…
View more
Added:
1 week ago
HFA Congress 2026 — Dr Rui Baptista (University of Coimbra, Coimbra, PT) joins us to discuss findings from the PORTHOS (PORTuguese Heart Failure Observational Study), a nationwide, population-based epidemiological study examining heart failure prevalence and characteristics in mainland Portugal using contemporary diagnostic tools.PORTHOS enrolled 6,189 adults aged 50 and above, randomly selected…
View more
Added:
9 months ago
Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) discuss the most anticipated hot line studies to be unveiled at ESC Congress 2025. Tune in for their in-depth analysis to get ahead of the curve.ESC Congress 2025 Hot Line Trials Discussed:VICTORVICTORIADIGIT-HFDAPA-ACT-HF-TIMIREBOOT-CNICBETAMI-DANBLOCKREFINE ICDStay tuned for Radcliffe Cardiology’s in-depth…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 - Dr Clyde Yancy (Northwestern University, US) joins us to explore the future trajectory of heart failure management, examining how prevention strategies, precision medicine approaches, and the evolving responsibilities of cardiologists are reshaping patient outcomes.Interview Questions:Looking at the current state of heart failure management, what do you see as the…
View more
Added:
2 weeks ago
In this episode of Masterclass, host, Dr Harriette Van Spall speaks with Professor Faiez Zannad about the challenge of making heart failure evidence more globally representative.Professor Zannad is an emeritus Professor of Therapeutics and Cardiology at the University of Lorraine in Nancy, France, and a leading clinical trialist in heart failure whose studies have informed international treatment…
View more
Added:
8 months ago
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.Trials covered in detail include:REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionBETAMI-DANBLOCK: Beta-Blockers after Myocardial…
View more
Added:
9 months ago
ESC Congress 2025 - Vericiguat did not reduce the risk of cardiovascular mortality and hospitalization in heart failure with reduced ejection fraction, fewer cardiovascular deaths and all-cause deaths were observed.Host, Dr Harriette Van Spall (McMaster University, CA) is joined on-site at ESC Congress 2025 in Madrid by Dr Faiez Zannad (University of Lorraine, FR) to discuss pivotal results from…
View more
Added:
2 months ago
ACC.26 - In this expert interview filmed at ACC.26 in New Orleans, Prof. Felipe Martínez discusses how late-breaking heart failure data are reshaping contemporary pharmacological management. The conversation focuses on new spironolactone results, advanced hemodynamic strategies in HFpEF, and the expanding role of cardiometabolic therapies, including GLP‑1 receptor agonists, in optimising outcomes…
View more
Added:
1 year ago
In this short video, Dr Ovidiu Chioncel shares why acute heart failure remains a critical area of focus in cardiology, highlighting the urgent need for improved strategies in diagnosis and management.This conversation sets the stage for his upcoming Special Focus in Cardiac Failure Review (Impact Factor: 4.2) in 2026, which will explore this topic further.
View more